Levonorgestrel side effects: what 200,207 FDA adverse event reports show
Drug class
Progestin, Progestin-containing Intrauterine System
Brand names
Liletta
Who reports
200,207 reports · 33% serious · 268 with death outcome · 99% female
Used for
LILETTA is a progestin-containing intrauterine system indicated for: Prevention of pregnancy for up to 8 years ( 1.1 ) Treatment of heavy menstrual bleeding for up to 5 years in patients who choose intrauterine contraception as their method of contraception ( 1.2 ) 1.1 Contraception LILETTA is indicated for prevention of pregnancy for up to 8 years.
What it is
Levonorgestrel is the ()-enantiomer of norgestrel. It has a role as a female contraceptive drug, a synthetic oral contraceptive and a progestin.
Boxed warning
None in the current label
Causality screen of the 40 strongest signals
What the badges mean
- Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,209 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Intra-uterine contraceptive device expelled | 5,573 | 11,640.9 8,787.5–15,420.8ROR 11,974.2 · calibrated p 2e-31 ✓ | 102.4 EB05 100.2 · IC025 +6.6 3/3 methods agree vs other Progestins: only this drug | Labeled (related wording) related wording | serious n=129 | not reported in cached trials |
| Ectopic pregnancy with intrauterine device | 291 | 2,707.7 1,483.0–4,943.6ROR 2,711.6 · calibrated p 1e-19 ✓ | 99.0 EB05 89.8 · IC025 +6.2 3/3 methods agree vs other Progestins: only this drug | Labeled (related wording) related wording | serious n=291 | not reported in cached trials |
| Iucd complication | 2,440 | 1,560.9 1,330.2–1,831.5ROR 1,580.1 · calibrated p 2e-19 ✓ | 96.9 EB05 93.7 · IC025 +6.5 3/3 methods agree vs other Progestins: only this drug | Reporting / coding artifact | serious n=567 | not reported in cached trials |
| Medical device monitoring error | 253 | 1,233.1 790.1–1,924.4ROR 1,234.6 · calibrated p 6e-17 ✓ | 94.8 EB05 85.4 · IC025 +6.1 3/3 methods agree vs other Progestins: only this drug | Not in label — unassessed | serious n=131 | not reported in cached trials |
| Iud migration | 793 | 1,143.2 896.8–1,457.3ROR 1,147.7 · calibrated p 1e-17 ✓ | 94.6 EB05 89.2 · IC025 +6.4 3/3 methods agree vs other Progestins: only this drug | Labeled (related wording) related wording | serious n=775 | not reported in cached trials |
| Unintentional medical device removal by patient | 29 | 989.4 301.4–3,248.0ROR 989.5 · calibrated p 8e-11 ✓ | 88.4 EB05 64.5 · IC025 +4.6 3/3 methods agree vs other Progestins: only this drug | Labeled (related wording) related wording | – | not reported in cached trials |
| Uterine perforation | 7,439 | 759.1 710.8–810.7ROR 788.4 · calibrated p 4e-16 ✓ | 91.1 EB05 89.3 · IC025 +6.5 3/3 methods agree vs other Progestins: only this drug | Labeled adverse reaction exact term | serious PRR 159.9 | not reported in cached trials |
| Contraindicated device used | 281 | 737.5 527.6–1,030.8ROR 738.5 · calibrated p 4e-15 ✓ | 90.2 EB05 81.7 · IC025 +6.1 3/3 methods agree vs other Progestins: only this drug | Reporting / coding artifact | serious n=138 | not reported in cached trials |
| Pregnancy after post coital contraception | 1,963 | 712.5 628.9–807.1ROR 719.5 · calibrated p 1e-15 ✓ | 90.3 EB05 87.0 · IC025 +6.4 3/3 methods agree vs other Progestins: only this drug | Labeled (related wording) related wording | serious n=1,571 · 99% consumer | not reported in cached trials |
| Genital haemorrhage | 11,128 | 693.6 658.7–730.4ROR 734.4 · calibrated p 9e-16 ✓ | 90.0 EB05 88.7 · IC025 +6.5 3/3 methods agree vs other Progestins: PRR 3,218.0 (2,394.1–4,325.6) | Not in label — unassessed | serious PRR 156.1 | not reported in cached trials |
| Uterine cervix stenosis | 445 | 576.5 453.9–732.4ROR 577.8 · calibrated p 3e-14 ✓ | 87.4 EB05 80.8 · IC025 +6.2 3/3 methods agree vs other Progestins: only this drug | Not in label — unassessed | serious n=75 | not reported in cached trials |
| Post procedural discomfort | 1,693 | 485.4 433.1–544.0ROR 489.5 · calibrated p 8e-14 ✓ | 85.3 EB05 81.9 · IC025 +6.3 3/3 methods agree vs other Progestins: only this drug | Reporting / coding artifact | serious n=442 | not reported in cached trials |
| Intra-uterine contraceptive device removal | 208 | 367.1 274.4–491.0ROR 367.4 · calibrated p 4e-12 ✓ | 80.2 EB05 71.5 · IC025 +5.9 3/3 methods agree vs other Progestins: only this drug | Labeled (related wording) related wording | serious n=110 | not reported in cached trials |
| Ectopic pregnancy with contraceptive device | 1,265 | 310.5 278.0–346.8ROR 312.5 · calibrated p 7e-12 ✓ | 77.6 EB05 74.1 · IC025 +6.1 3/3 methods agree vs other Progestins: PRR 161.0 (131.4–197.2) | Labeled (related wording) related wording | serious n=1,265 | not reported in cached trials |
| Uterine rupture | 1,020 | 265.6 236.5–298.4ROR 267.0 · calibrated p 3e-11 ✓ | 74.5 EB05 70.7 · IC025 +6.1 3/3 methods agree vs other Progestins: only this drug | Labeled (related wording) related wording | serious n=997 | not reported in cached trials |
| Device expulsion | 45,531 | 247.6 243.5–251.6ROR 320.1 · calibrated p 5e-12 ✓ | 73.1 EB05 72.6 · IC025 +6.2 3/3 methods agree vs other Progestins: PRR 261.7 (251.2–272.5) | Reporting / coding artifact | serious PRR 97.6 | not reported in cached trials |
| Medical device pain | 1,503 | 244.6 222.9–268.4ROR 246.4 · calibrated p 6e-11 ✓ | 72.8 EB05 69.8 · IC025 +6.1 3/3 methods agree vs other Progestins: PRR 2,732.0 (1,300.3–5,740.1) | Labeled (related wording) related wording | serious n=982 | not reported in cached trials |
| Medical device discomfort | 2,113 | 235.8 218.3–254.8ROR 238.3 · calibrated p 8e-11 ✓ | 72.0 EB05 69.5 · IC025 +6.1 3/3 methods agree vs other Progestins: PRR 353.8 (281.5–444.6) | Labeled (related wording) related wording | serious n=1,180 | not reported in cached trials |
| Pregnancy with contraceptive device | 5,946 | 205.3 196.5–214.5ROR 211.5 · calibrated p 2e-10 ✓ | 68.9 EB05 67.5 · IC025 +6.1 3/3 methods agree vs other Progestins: PRR 879.7 (711.3–1,088.0) | Labeled (related wording) related wording | serious PRR 113.9 | not reported in cached trials |
| Uterine stenosis | 25 | 159.9 85.4–299.5ROR 159.9 · calibrated p 5e-8 ✓ | 60.3 EB05 42.9 · IC025 +4.2 3/3 methods agree vs other Progestins: only this drug | Not in label — unassessed | – | not reported in cached trials |
| Gynaecological chlamydia infection | 31 | 144.2 83.5–249.1ROR 144.2 · calibrated p 6e-8 ✓ | 58.4 EB05 43.1 · IC025 +4.4 3/3 methods agree vs other Progestins: only this drug | Labeled (related wording) related wording | serious n=28 · 100% clinician | not reported in cached trials |
| Medical device entrapment | 44 | 140.7 89.3–221.9ROR 140.8 · calibrated p 4e-8 ✓ | 58.4 EB05 45.3 · IC025 +4.7 3/3 methods agree vs other Progestins: only this drug | Not in label — unassessed | serious n=32 | not reported in cached trials |
| Menstruation irregular | 15,020 | 137.6 134.4–141.0ROR 148.7 · calibrated p 5e-9 ✓ | 59.3 EB05 58.5 · IC025 +5.9 3/3 methods agree vs other Progestins: PRR 81.7 (78.4–85.2) | Labeled (related wording) related wording | serious n=825 · 96% consumer | not reported in cached trials |
| Coital bleeding | 857 | 136.0 122.8–150.6ROR 136.6 · calibrated p 1e-8 ✓ | 58.9 EB05 55.7 · IC025 +5.7 3/3 methods agree vs other Progestins: PRR 302.9 (217.1–422.7) | Labeled (related wording) related wording | serious n=368 · 71% consumer | not reported in cached trials |
| Menstruation delayed | 5,759 | 131.2 126.2–136.3ROR 135.0 · calibrated p 1e-8 ✓ | 58.0 EB05 56.8 · IC025 +5.8 3/3 methods agree vs other Progestins: PRR 136.7 (125.3–149.2) | Labeled (related wording) related wording | serious n=393 · 97% consumer | not reported in cached trials |
| Ruptured ectopic pregnancy | 422 | 124.1 107.7–143.0ROR 124.4 · calibrated p 2e-8 ✓ | 56.5 EB05 52.1 · IC025 +5.6 3/3 methods agree vs other Progestins: PRR 167.8 (117.2–240.3) | Labeled (related wording) related wording | serious n=422 | not reported in cached trials |
| Fallopian tube perforation | 49 | 122.3 80.8–185.2ROR 122.4 · calibrated p 8e-8 ✓ | 55.1 EB05 43.3 · IC025 +4.7 3/3 methods agree vs other Progestins: only this drug | Not in label — unassessed | serious n=49 · 76% consumer | not reported in cached trials |
| Device implantation error | 45 | 115.1 75.2–176.3ROR 115.2 · calibrated p 1e-7 ✓ | 53.5 EB05 41.7 · IC025 +4.6 3/3 methods agree vs other Progestins: PRR 22.0 (13.6–35.7) | Reporting / coding artifact | 100% clinician | not reported in cached trials |
| Uterine spasm | 944 | 111.3 101.5–122.0ROR 111.8 · calibrated p 5e-8 ✓ | 53.8 EB05 51.0 · IC025 +5.6 3/3 methods agree vs other Progestins: PRR 572.0 (371.2–881.3) | Labeled adverse reaction exact term | serious n=231 | not reported in cached trials |
| Device misuse | 681 | 108.7 97.6–121.1ROR 109.1 · calibrated p 6e-8 ✓ | 53.2 EB05 49.9 · IC025 +5.6 3/3 methods agree vs other Progestins: only this drug | Reporting / coding artifact | serious n=399 | not reported in cached trials |
| Loop electrosurgical excision procedure | 72 | 106.8 76.8–148.6ROR 106.8 · calibrated p 1e-7 ✓ | 52.1 EB05 42.8 · IC025 +4.9 3/3 methods agree vs other Progestins: only this drug | Reporting / coding artifact | serious n=41 | not reported in cached trials |
| Uterine cervical pain | 94 | 103.5 77.7–137.8ROR 103.5 · calibrated p 2e-7 ✓ | 51.4 EB05 43.3 · IC025 +5.0 3/3 methods agree vs other Progestins: only this drug | Labeled (related wording) related wording | serious n=64 | not reported in cached trials |
| Internal injury | 324 | 102.0 87.5–119.0ROR 102.2 · calibrated p 1e-7 ✓ | 51.4 EB05 46.9 · IC025 +5.4 3/3 methods agree vs other Progestins: only this drug | Not in label — unassessed | serious n=324 | not reported in cached trials |
| Uterine scar | 109 | 97.0 74.7–126.1ROR 97.1 · calibrated p 2e-7 ✓ | 49.9 EB05 42.5 · IC025 +5.0 3/3 methods agree vs other Progestins: only this drug | Labeled (related wording) related wording | serious n=99 | not reported in cached trials |
| Device dislocation | 20,441 | 93.4 91.7–95.2ROR 104.0 · calibrated p 8e-8 ✓ | 49.3 EB05 48.8 · IC025 +5.6 3/3 methods agree vs other Progestins: PRR 94.8 (91.3–98.5) | Reporting / coding artifact | age-adj. PRR 65.6 · serious PRR 82.4 | not reported in cached trials |
| Uterine fibrosis | 28 | 89.6 53.9–148.7ROR 89.6 · calibrated p 1e-6 ✓ | 46.8 EB05 34.0 · IC025 +4.1 3/3 methods agree vs other Progestins: only this drug | Not in label — unassessed | serious n=25 | not reported in cached trials |
| Hypomenorrhoea | 1,161 | 84.0 77.7–90.7ROR 84.5 · calibrated p 4e-7 ✓ | 46.5 EB05 44.3 · IC025 +5.4 3/3 methods agree vs other Progestins: PRR 61.6 (53.6–70.7) | Not in label — unassessed | serious n=323 · 85% consumer | not reported in cached trials |
| Device component issue | 67 | 83.6 60.6–115.5ROR 83.7 · calibrated p 8e-7 ✓ | 45.9 EB05 37.4 · IC025 +4.7 3/3 methods agree vs other Progestins: only this drug | Reporting / coding artifact | serious n=34 · 71% consumer | not reported in cached trials |
| Cervix injury | 30 | 80.8 50.1–130.4ROR 80.8 · calibrated p 2e-6 ✓ | 44.4 EB05 32.6 · IC025 +4.1 3/3 methods agree vs other Progestins: only this drug | Not in label — unassessed | serious n=24 · 100% clinician | not reported in cached trials |
| Dyspareunia | 1,978 | 79.3 74.8–84.1ROR 80.1 · calibrated p 6e-7 ✓ | 45.1 EB05 43.5 · IC025 +5.4 3/3 methods agree vs other Progestins: PRR 433.9 (334.3–563.2) | Labeled adverse reaction exact term | serious n=1,103 | not reported in cached trials |
Clinical concept groups
MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.
| Concept | Reports | PRR 95% CI | Reading |
|---|---|---|---|
| Depression | 5,557 | 2.12.0–2.1 | signal |
| Opportunistic infection | 625 | 0.50.4–0.5 | lower than other drugs |
| Suicidality | 892 | 0.40.4–0.4 | lower than other drugs |
| Venous thromboembolism | 758 | 0.40.3–0.4 | lower than other drugs |
| Tendon disorder | 108 | 0.30.2–0.4 | lower than other drugs |
| Serious infection | 2,180 | 0.30.3–0.3 | lower than other drugs |
| Seizure | 504 | 0.30.2–0.3 | lower than other drugs |
| Malignancy | 631 | 0.20.2–0.2 | lower than other drugs |
| Anaphylaxis / angioedema | 205 | 0.20.1–0.2 | lower than other drugs |
| Anaemia | 427 | 0.10.1–0.2 | lower than other drugs |
| Stroke | 284 | 0.10.1–0.1 | lower than other drugs |
| Pancreatitis | 84 | 0.10.1–0.1 | lower than other drugs |
| Liver injury | 253 | 0.10.1–0.1 | lower than other drugs |
| Arrhythmia / qt | 149 | 0.10.1–0.1 | lower than other drugs |
| Extrapyramidal | 69 | 0.10.1–0.1 | lower than other drugs |
| Hypoglycaemia | 59 | 0.10.0–0.1 | lower than other drugs |
Trial evidence (ClinicalTrials.gov)
✓ Trial adverse-event data found on ClinicalTrials.gov
Largest completed trials with posted results that list Levonorgestrel as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (0 of 40 signal terms matched).
- NCT00302848 — European Active Surveillance Study (EURAS) (N=59510, phase n/a; 15 AE terms posted; arms: Users of Drospirenone (DRSP); Users of Levonorgestrel (LNG); Users of Other Oral Contraceptives (OCs))
Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Device expulsion | 45,531 | 247.6 243.5–251.6ROR 320.1 · calibrated p 5e-12 ✓ | 73.1 EB05 72.6 · IC025 +6.2 3/3 methods agree vs other Progestins: PRR 261.7 (251.2–272.5) | Reporting / coding artifact | serious PRR 97.6 | not reported in cached trials |
| Device dislocation | 20,441 | 93.4 91.7–95.2ROR 104.0 · calibrated p 8e-8 ✓ | 49.3 EB05 48.8 · IC025 +5.6 3/3 methods agree vs other Progestins: PRR 94.8 (91.3–98.5) | Reporting / coding artifact | age-adj. PRR 65.6 · serious PRR 82.4 | not reported in cached trials |
| Menstruation irregular | 15,020 | 137.6 134.4–141.0ROR 148.7 · calibrated p 5e-9 ✓ | 59.3 EB05 58.5 · IC025 +5.9 3/3 methods agree vs other Progestins: PRR 81.7 (78.4–85.2) | Labeled (related wording) related wording | serious n=825 · 96% consumer | not reported in cached trials |
| Vaginal haemorrhage | 14,926 | 56.4 55.3–57.5ROR 60.9 · calibrated p 4e-6 ✓ | 36.7 EB05 36.2 · IC025 +5.2 3/3 methods agree vs other Progestins: PRR 66.3 (63.8–68.8) | Not in label — unassessed | age-adj. PRR 37.4 · serious PRR 33.6 · 80% consumer | not reported in cached trials |
| Genital haemorrhage | 11,128 | 693.6 658.7–730.4ROR 734.4 · calibrated p 9e-16 ✓ | 90.0 EB05 88.7 · IC025 +6.5 3/3 methods agree vs other Progestins: PRR 3,218.0 (2,394.1–4,325.6) | Not in label — unassessed | serious PRR 156.1 | not reported in cached trials |
| Abdominal pain lower | 9,293 | 60.5 58.9–62.0ROR 63.3 · calibrated p 3e-6 ✓ | 38.4 EB05 37.7 · IC025 +5.2 3/3 methods agree vs other Progestins: PRR 646.1 (558.5–747.5) | Labeled (related wording) related wording | age-adj. PRR 49.7 · serious PRR 52.0 | not reported in cached trials |
| Abdominal pain | 8,588 | 4.0 3.9–4.1ROR 4.1 · calibrated p 0.357 | 3.9 EB05 3.8 · IC025 +1.9 3/3 methods agree vs other Progestins: PRR 134.4 (125.2–144.3) | Labeled adverse reaction exact term | age-adj. PRR 3.2 · serious PRR 4.9 | not reported in cached trials |
| Nausea | 8,519 | 1.1 1.1–1.2ROR 1.1 · calibrated p 0.398 | 1.1 EB05 1.1 · IC025 +0.1 vs other Progestins: PRR 65.4 (62.2–68.8) | Labeled adverse reaction exact term | age-adj. PRR 0.9 · serious PRR 1.1 · 86% consumer | not reported in cached trials |
| Procedural pain | 8,458 | 46.0 44.8–47.1ROR 47.9 · calibrated p 2e-5 ✓ | 32.0 EB05 31.5 · IC025 +5.0 3/3 methods agree vs other Progestins: PRR 1,098.2 (900.3–1,339.6) | Not in label — unassessed | age-adj. PRR 46.0 · serious PRR 33.3 | not reported in cached trials |
| Pain | 7,530 | 1.3 1.3–1.3ROR 1.3 · calibrated p 0.505 | 1.3 EB05 1.3 · IC025 +0.3 vs other Progestins: PRR 77.8 (73.4–82.6) | Labeled adverse reaction exact term | age-adj. PRR 1.3 · serious PRR 2.7 | not reported in cached trials |
| Uterine perforation | 7,439 | 759.1 710.8–810.7ROR 788.4 · calibrated p 4e-16 ✓ | 91.1 EB05 89.3 · IC025 +6.5 3/3 methods agree vs other Progestins: only this drug | Labeled adverse reaction exact term | serious PRR 159.9 | not reported in cached trials |
| Drug ineffective (drug did not work) | 7,152 | 0.6 0.6–0.6ROR 0.6 · calibrated p 0.065 | 0.6 EB05 0.6 · IC025 -0.9 PRR-only: not supported by EBGM or IC vs other Progestins: PRR 244.6 (220.6–271.3) | Reporting / coding artifact | age-adj. PRR 0.6 · serious PRR 2.3 | not reported in cached trials |
| Pelvic pain | 6,853 | 63.2 61.3–65.1ROR 65.4 · calibrated p 2e-6 ✓ | 39.4 EB05 38.7 · IC025 +5.3 3/3 methods agree vs other Progestins: PRR 192.1 (174.8–211.0) | Labeled adverse reaction exact term | serious PRR 52.9 | not reported in cached trials |
| Headache | 6,451 | 1.1 1.1–1.1ROR 1.1 · calibrated p 0.361 | 1.1 EB05 1.1 · IC025 +0.1 vs other Progestins: PRR 39.4 (37.6–41.3) | Labeled adverse reaction exact term | age-adj. PRR 0.9 · serious PRR 1.8 · 78% consumer | not reported in cached trials |
| Pregnancy with contraceptive device | 5,946 | 205.3 196.5–214.5ROR 211.5 · calibrated p 2e-10 ✓ | 68.9 EB05 67.5 · IC025 +6.1 3/3 methods agree vs other Progestins: PRR 879.7 (711.3–1,088.0) | Labeled (related wording) related wording | serious PRR 113.9 | not reported in cached trials |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Medical device monitoring error — n=253, PRR 1,233.1
- Genital haemorrhage — n=11,128, PRR 693.6
- Uterine cervix stenosis — n=445, PRR 576.5
- Uterine stenosis — n=25, PRR 159.9
- Medical device entrapment — n=44, PRR 140.7
- Fallopian tube perforation — n=49, PRR 122.3
- Internal injury — n=324, PRR 102.0
- Uterine fibrosis — n=28, PRR 89.6
- Hypomenorrhoea — n=1,161, PRR 84.0
- Cervix injury — n=30, PRR 80.8
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Levonorgestrel?
In FDA FAERS, the most frequently co-reported reaction terms for Levonorgestrel are menstruation irregular, vaginal haemorrhage, genital haemorrhage, abdominal pain lower, abdominal pain, nausea. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Levonorgestrel have an FDA boxed warning?
No. The FDA label retrieved for Levonorgestrel has no boxed warning; see the label's Warnings and Precautions for the recognised risks.
Do FAERS signals prove that Levonorgestrel causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID aaf0eb2a-f88a-4f26-a445-0fd30176c326, effective 20230629; matched on
openfda.generic_name.exact:"LEVONORGESTREL" AND openfda.product_type:"HUMAN PRESCRIPTION DRUG") - PubChem CID 13109 description (ChEBI)
- Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,249 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
LEVONORGESTREL, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.